Therapeutic effectiveness against mopc—315 plasmacytoma of low or high doses of the synthetic thymic hormone THF—γ2 in combination with an “immunomodulating” or a “non—immunomodulating” drug
✍ Scribed by R. Ophir; M. Pecht; Y. Burstein; H. Harshemesh; S. Ben-Efraim; N. Trainin
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- French
- Weight
- 453 KB
- Volume
- 48
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
We reported previously that treatment of mice bearing MOPC-3 I5 plasmacytoma with the drugs L-PAM (phenylalanine mustard or 5-FU (5-fluorouracil), in combination with survival time than treatment with the drug alone. We show here that in the combined treatment using a single injection of 5-FU followed by multiple (&IS) injections of THF-72, the megadoses were more effective than the low doses in increasing the survival time of MOPC-315 tumor-bearing mice. On the other hand, in combination with L-PAM, both low and high doses of THF-y2 were equally effective. The need for high doses of THF-y2, when used in combination with 5-FU, could be due to the fact that 5-FU acts as a "non-immunomodulating" drug and has to be used at a high, immunosuppressive dose. low doses of 4 HF-72, was more effective in increasing their
Combined chemocherapy and THF-y2 treatment
Mice inoculated S.C. with 2 x lo5 MOPC-315 tumor cells received on the 7th day after inoculation a single dose of either 5-FU or L-PAM. Parallel groups of TB mice were also treated with THF-y2 in addition to chemotherapy. In order to allow a comparison with previously reported results (Ophir et al., 1989; Trainin et al., 1987), THF-y2 was injected i.p. in mice treated with 5-FU and i.m. in mice treated with L-PAM. A "mega" dose consisting of 50 p,g per injection of THF-y2 was BALBIc mice, 8-12 weeks old, from the breeding colony of 4T0 whom correspondence and reprint requests should be sent, at the